Covered recipient · General Payments record
DIONISIO B YORRO
Allopathic & Osteopathic Physicians Emergency Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,436.84
68 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,436.84 | 68 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $443.11 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $253.81 | 10 |
| Novo Nordisk Inc | $182.43 | 15 |
| Novartis Pharmaceuticals Corporation | $140.72 | 10 |
| Merck Sharp & Dohme LLC | $85.65 | 4 |
| ABBVIE INC. | $73.99 | 4 |
| SANOFI-AVENTIS U.S. LLC | $71.09 | 3 |
| Esperion Therapeutics, Inc. | $62.16 | 3 |
| Lilly USA, LLC | $52.34 | 3 |
| PFIZER INC. | $35.08 | 2 |
| IDORSIA PHARMACEUTICALS US INC | $20.75 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 1 |
Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DIONISIO B YORRO
NPI 1942245147 · CMS profile ID 1295309
Allopathic & Osteopathic Physicians / Emergency Medicine
GURNEE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- DIONISIO B YORRO, NPI 1942245147, CMS profile ID 1295309, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942245147?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
68 matching records · $1,436.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–68 of 68.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.24 | 04/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997092681 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016397915 | CMS |
| PFIZER INC. | $18.96 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050391259 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.42 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015916097 | CMS |
| Esperion Therapeutics, Inc. | $19.40 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050749461 | CMS |
| Merck Sharp & Dohme LLC | $19.98 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048348149 | CMS |
| Novo Nordisk Inc | $15.81 | 03/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000411087 | CMS |
| Novartis Pharmaceuticals Corporation | $16.34 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993412587 | CMS |
| Novo Nordisk Inc | $6.77 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000411041 | CMS |
| Lilly USA, LLC | $13.36 | 03/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031460637 | CMS |
| SANOFI-AVENTIS U.S. LLC | $14.64 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049628019 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.14 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997149277 | CMS |
| Merck Sharp & Dohme LLC | $22.36 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048348117 | CMS |
| Novo Nordisk Inc | $4.94 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000411007 | CMS |
| Novo Nordisk Inc | $11.01 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000411057 | CMS |
| ABBVIE INC. | $21.06 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1061399874 | CMS |
| ABBVIE INC. | $12.85 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1061399876 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.93 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015894083 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $75,470.00 | 86 |
| PY2024 | Recipient | $50,126.00 | 35 |
| PY2023 | Recipient | $30,526.00 | 35 |
| PY2022 | Recipient | $74,554.00 | 88 |
| PY2021 | Recipient | $44,830.00 | 79 |
| PY2020 | Recipient | $30,828.00 | 53 |
| PY2019 | Recipient | $10,249.00 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | ABBVIE INC. | $3,260.00 | 12/05/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402872 |
| Recipient | ABBVIE INC. | $620.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND IMMUNOGENICITY OF ABBV-277 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1202402877 |
| Recipient | ABBVIE INC. | $860.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SC INJECTIONS AND IV INFUSTIONS OF ABBV-142 MOVE THROUGH THE BODY OF ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402880 |
| Recipient | ABBVIE INC. | $120.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO EVALUATE ADVERSE EVENTS HOW DRUG IS TOLERATED AND MOVES THROUGH THE BODY OF ABBV-8736 | No dispute reported | 06/30/2026 | 1202402884 |
| Recipient | ABBVIE INC. | $270.00 | 12/05/2025 | Covered Recipient Physician | ARMOUR THYROID STUDY | No dispute reported | 06/30/2026 | 1202402888 |
| Recipient | ABBVIE INC. | $1,690.00 | 12/05/2025 | Covered Recipient Physician | how the drug moves through the body and tolerability of orabl abbv-722capsules | No dispute reported | 06/30/2026 | 1202402892 |
| Recipient | ABBVIE INC. | $30.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ACCENDING DOSE, DRUG DRUG INTERACTION AND ASIAN PHARMACOKINETIC STUDY OF ABBV-1008 | No dispute reported | 06/30/2026 | 1202402896 |
| Recipient | ABBVIE INC. | $1,350.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND IMMUNOGENICITY OF SINGLE ASCENDING SUBCUTANEOUS OR IV DOESES OF ABBV-701 | No dispute reported | 06/30/2026 | 1202402899 |
| Recipient | ABBVIE INC. | $1,090.00 | 12/05/2025 | Covered Recipient Physician | A STUDY TO EVALUATE ADVERSE EVENTS HOW DRUG IS TOLERATED AND MOVES THROUGH THE BODY | No dispute reported | 06/30/2026 | 1202402903 |
| Recipient | ABBVIE INC. | $6,560.00 | 11/13/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402833 |
| Recipient | ABBVIE INC. | $150.00 | 11/13/2025 | Covered Recipient Physician | A STUDY TO ASSESS HOW THE DRUG MOVES THROUGH THE BODY ABBV-722 | No dispute reported | 06/30/2026 | 1202402838 |
| Recipient | ABBVIE INC. | $1,220.00 | 11/13/2025 | Covered Recipient Physician | a study to evaluate the safety tolerability pharmacokinetics and immunogenicity of ABBV-701 | No dispute reported | 06/30/2026 | 1202402842 |
| Recipient | ABBVIE INC. | $10.00 | 11/13/2025 | Covered Recipient Physician | ASESS HOW FOOD AFFECTS THE MOVEMENT OF ORAB ABBV-101 THROUGH THE BODY | No dispute reported | 06/30/2026 | 1202402846 |
| Recipient | ABBVIE INC. | $290.00 | 11/13/2025 | Covered Recipient Physician | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202402849 |
| Recipient | ABBVIE INC. | $1,540.00 | 11/13/2025 | Covered Recipient Physician | ASSESS THE ADVERSE EVENTS AND HOW SC AND IV OF ABBV-142 MOVE THROUGH THE BODY | No dispute reported | 06/30/2026 | 1202402853 |
| Recipient | ABBVIE INC. | $210.00 | 11/13/2025 | Covered Recipient Physician | evaulate the bioavailabilty and food effects of oral venetoclax | No dispute reported | 06/30/2026 | 1202402857 |
| Recipient | ABBVIE INC. | $330.00 | 11/13/2025 | Covered Recipient Physician | A study to assess the relative bioavailabilty of oral abbv-932 in healthy adults | No dispute reported | 06/30/2026 | 1202402861 |
| Recipient | ABBVIE INC. | $140.00 | 11/13/2025 | Covered Recipient Physician | M25-966 Nimble Ph 1 TL1A UC DDI Study (n=16) | No dispute reported | 06/30/2026 | 1202402865 |
| Recipient | ABBVIE INC. | $80.00 | 11/13/2025 | Covered Recipient Physician | a study to evaluate the safety tolerability pharmacokinetics and immunogenicity of abbv-277 | No dispute reported | 06/30/2026 | 1202402869 |
| Recipient | ABBVIE INC. | $330.00 | 10/09/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402788 |
| Recipient | ABBVIE INC. | $1,740.00 | 10/09/2025 | Covered Recipient Physician | ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY | No dispute reported | 06/30/2026 | 1202402792 |
| Recipient | ABBVIE INC. | $530.00 | 10/09/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402798 |
| Recipient | ABBVIE INC. | $1,680.00 | 10/09/2025 | Covered Recipient Physician | EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES | No dispute reported | 06/30/2026 | 1202402802 |
| Recipient | ABBVIE INC. | $50.00 | 10/09/2025 | Covered Recipient Physician | no details on this study are available | No dispute reported | 06/30/2026 | 1202402805 |
| Recipient | ABBVIE INC. | $550.00 | 10/09/2025 | Covered Recipient Physician | A study to assess the relative bioavailability of risankizumab | No dispute reported | 06/30/2026 | 1202402809 |
| Recipient | ABBVIE INC. | $1,140.00 | 10/09/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402812 |
| Recipient | ABBVIE INC. | $490.00 | 10/09/2025 | Covered Recipient Physician | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402815 |
| Recipient | ABBVIE INC. | $310.00 | 10/09/2025 | Covered Recipient Physician | Nimble Phase1 TL1A UCDDI study | No dispute reported | 06/30/2026 | 1202402818 |
| Recipient | ABBVIE INC. | $520.00 | 10/09/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402822 |
| Recipient | ABBVIE INC. | $950.00 | 10/09/2025 | Covered Recipient Physician | PHASE 1 SAD MAD STUDY | No dispute reported | 06/30/2026 | 1202402826 |
| Recipient | ABBVIE INC. | $1,140.00 | 10/09/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402829 |
| Recipient | ABBVIE INC. | $550.00 | 09/11/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402740 |
| Recipient | ABBVIE INC. | $190.00 | 09/11/2025 | Covered Recipient Physician | A study to assess the relative bioavailability of risankizumab | No dispute reported | 06/30/2026 | 1202402744 |
| Recipient | ABBVIE INC. | $790.00 | 09/11/2025 | Covered Recipient Physician | EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES | No dispute reported | 06/30/2026 | 1202402748 |
| Recipient | ABBVIE INC. | $840.00 | 09/11/2025 | Covered Recipient Physician | A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402752 |
| Recipient | ABBVIE INC. | $270.00 | 09/11/2025 | Covered Recipient Physician | A study to assess the relative bioavailability of risankizumab | No dispute reported | 06/30/2026 | 1202402757 |
| Recipient | ABBVIE INC. | $290.00 | 09/11/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402761 |
| Recipient | ABBVIE INC. | $3,010.00 | 09/11/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402765 |
| Recipient | ABBVIE INC. | $120.00 | 09/11/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402769 |
| Recipient | ABBVIE INC. | $160.00 | 09/11/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402772 |
| Recipient | ABBVIE INC. | $700.00 | 09/11/2025 | Covered Recipient Physician | PHASE 1 SAD MAD STUDY | No dispute reported | 06/30/2026 | 1202402775 |
| Recipient | ABBVIE INC. | $2,930.00 | 09/11/2025 | Covered Recipient Physician | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402780 |
| Recipient | ABBVIE INC. | $1,490.00 | 09/11/2025 | Covered Recipient Physician | ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY | No dispute reported | 06/30/2026 | 1202402784 |
| Recipient | ABBVIE INC. | $1,260.00 | 08/01/2025 | Covered Recipient Physician | PHASE 1 SAD MAD STUDY | No dispute reported | 06/30/2026 | 1202402668 |
| Recipient | ABBVIE INC. | $2,490.00 | 08/01/2025 | Covered Recipient Physician | A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402672 |
| Recipient | ABBVIE INC. | $1,280.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402675 |
| Recipient | ABBVIE INC. | $1,000.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402679 |
| Recipient | ABBVIE INC. | $600.00 | 08/01/2025 | Covered Recipient Physician | EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES | No dispute reported | 06/30/2026 | 1202402685 |
| Recipient | ABBVIE INC. | $120.00 | 08/01/2025 | Covered Recipient Physician | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402688 |
| Recipient | ABBVIE INC. | $200.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402692 |
| Recipient | ABBVIE INC. | $1,050.00 | 08/01/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402695 |
| Recipient | ABBVIE INC. | $190.00 | 08/01/2025 | Covered Recipient Physician | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Ascending Oral Doses of ABBV-848 in Healthy Adult Subjects | No dispute reported | 06/30/2026 | 1202402699 |
| Recipient | ABBVIE INC. | $1,400.00 | 08/01/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402702 |
| Recipient | ABBVIE INC. | $980.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402706 |
| Recipient | ABBVIE INC. | $160.00 | 08/01/2025 | Covered Recipient Physician | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402709 |
| Recipient | ABBVIE INC. | $1,110.00 | 08/01/2025 | Covered Recipient Physician | ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY | No dispute reported | 06/30/2026 | 1202402713 |
| Recipient | ABBVIE INC. | $670.00 | 08/01/2025 | Covered Recipient Physician | EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND IMMUNGENICITY OF SINCLE ASCENDING SUBCUTANEOUS DOSES | No dispute reported | 06/30/2026 | 1202402717 |
| Recipient | ABBVIE INC. | $930.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402721 |
| Recipient | ABBVIE INC. | $1,780.00 | 08/01/2025 | Covered Recipient Physician | A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402725 |
| Recipient | ABBVIE INC. | $2,810.00 | 08/01/2025 | Covered Recipient Physician | ASSESS HOW THE DRUG MOVES THROUGH THE BODY ADVERSE EVENTS AND TOLERABILITY | No dispute reported | 06/30/2026 | 1202402728 |
| Recipient | ABBVIE INC. | $1,160.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402732 |
| Recipient | ABBVIE INC. | $930.00 | 08/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402736 |
| Recipient | ABBVIE INC. | $790.00 | 05/30/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402637 |
| Recipient | ABBVIE INC. | $1,670.00 | 05/30/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402640 |
| Recipient | ABBVIE INC. | $90.00 | 05/30/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402645 |
| Recipient | ABBVIE INC. | $140.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402649 |
| Recipient | ABBVIE INC. | $2,170.00 | 05/30/2025 | Covered Recipient Physician | Assess how the drug moves through the body, adverse events, and tolerability of ABBV-722 | No dispute reported | 06/30/2026 | 1202402653 |
| Recipient | ABBVIE INC. | $1,270.00 | 05/30/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402656 |
| Recipient | ABBVIE INC. | $1,150.00 | 05/30/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402659 |
| Recipient | ABBVIE INC. | $80.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants | No dispute reported | 06/30/2026 | 1202402664 |
| Recipient | ABBVIE INC. | $250.00 | 05/01/2025 | Covered Recipient Physician | A study to assess the safety, tolerability and interactions of ABBV-CLS-616 oral tablets in healthy adult participants | No dispute reported | 06/30/2026 | 1202402615 |
| Recipient | ABBVIE INC. | $100.00 | 05/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF ORAL ABBV-932 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402618 |
| Recipient | ABBVIE INC. | $880.00 | 05/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS THE ADVERSE EVENTS AND HOW SUBCUTANEOUS INJECTIONS AND INTRAVENOUS INFUSIONS OF ABBV-142 MOVE THROUGH THE BODY OF HEALTHY PARTCIPLANTS | No dispute reported | 06/30/2026 | 1202402623 |
| Recipient | ABBVIE INC. | $1,230.00 | 05/01/2025 | Covered Recipient Physician | A STUDY TO ASSESS MULTIPLE ASCENDING DOSE, DRUG-DRUG INTERACTION AND ASIAN PARMACOKINETIC STUDY | No dispute reported | 06/30/2026 | 1202402626 |
| Recipient | ABBVIE INC. | $410.00 | 05/01/2025 | Covered Recipient Physician | A STUDY TO EVALUATE THE BIOAVAILABILITY AND FOOD EFFECTS OF ORAL VENETOCLAX NEW TABLET FORMULATION 2 IN HEALTHY ADULT FEMALE PARTICIPANTS | No dispute reported | 06/30/2026 | 1202402630 |
| Recipient | ABBVIE INC. | $1,080.00 | 05/01/2025 | Covered Recipient Physician | Assess how the drug moves through the body, adverse events, and tolerability of ABBV-722 | No dispute reported | 06/30/2026 | 1202402633 |
| Recipient | ABBVIE INC. | $170.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402577 |
| Recipient | ABBVIE INC. | $90.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402580 |
| Recipient | ABBVIE INC. | $50.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402584 |
| Recipient | ABBVIE INC. | $750.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402586 |
| Recipient | ABBVIE INC. | $420.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402591 |
| Recipient | ABBVIE INC. | $240.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402595 |
| Recipient | ABBVIE INC. | $980.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402599 |
| Recipient | ABBVIE INC. | $90.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402603 |
| Recipient | ABBVIE INC. | $160.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402607 |
| Recipient | ABBVIE INC. | $500.00 | 02/27/2025 | Covered Recipient Physician | ELECTROCARDIOGRAM INTERPRETATION SERVICES AND INTERPRETING ABNORMAL REPORTS FOR PHASE 1 STUDIES | No dispute reported | 06/30/2026 | 1202402610 |